Results 21 to 30 of about 48,364 (325)
Apixaban-Induced Hepatotoxicity
Cureus, 2022 Apixaban is widely used to prevent and manage thromboembolic disease. Due to it being fairly new in the market, we are still understanding its complete risk profile. We present a case of a 61-year-old female with no prior history of liver disease, who developed severe transaminitis shortly after the initiation of apixaban and started trending down ...
Ansari, Umair +3 more
openaire +2 more sources
Circulation, 2022 Background: Non–vitamin K oral anticoagulants have become the standard therapy for preventing stroke and ischemic thromboembolism in most patients with atrial fibrillation (AF).
H. Reinecke +16 more
semanticscholar +1 more source
Apixaban in Acute Coronary Syndromes [PDF]
Cardiovascular Therapeutics, 2010 Apixaban is an orally active, selective, direct-acting, reversible inhibitor of factor Xa that is under evaluation for the management of acute coronary syndromes (ACS). This article critically reviews the rationale and evidence for the use of anticoagulants in the long-term management of ACS, preliminary data for apixaban from the phase 2 apixaban for ...
John W. Eikelboom, Ganesan Karthikeyan
openaire +3 more sources
Frontiers in Pharmacology, 2023 Background: Although non-vitamin K antagonist oral anticoagulants (NOACs) are recommended over vitamin K antagonists (VKAs) in atrial fibrillation (AF) management, direct long-term head-to-head comparisons are lacking.
M. Grymonprez +4 more
semanticscholar +1 more source
TH Open, 2023 This retrospective study, utilizing U.S. electronic health record (EHR) data from January 2013 to December 2020, sought to assess whether rivaroxaban and apixaban had similar effectiveness and safety in the treatment of cancer-associated venous ...
K. S. Caroti +13 more
semanticscholar +1 more source
Apixaban Enhances Endogenous Fibrinolysis in Patients with Atrial Fibrillation [PDF]
, 2019 © The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology.AIMS: Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which ...
Arachchillage, Deepa RJ +7 more
core +3 more sources
Journal of Medical Case Reports, 2023 Background Apixaban is a non-vitamin K antagonist oral anticoagulant (NOACs) recently emerged as an effective alternative to conventional vitamin K antagonists (VKAs) in the treatment of several thromboembolic disorders.
V. Dalmastri +8 more
semanticscholar +1 more source
Compounded Apixaban Suspensions for Enteral Feeding Tubes [PDF]
, 2017 Objective: There is limited information on compounded apixaban formulations for administration via enteral feeding tubes. This study was designed to identify a suitable apixaban suspension formulation that is easy to prepare in a pharmacy setting, is ...
Caraballo, Maria +3 more
core +2 more sources
The year in cardiology: arrhythmias and pacing. [PDF]
, 2020 During this last year, there has been much progress with regard to anticoagulant and ablation therapy for atrial fibrillation (AF). Apart from recently issued European Society of Cardiology Guidelines for the management of patients with supraventricular ...
Calkins, H +4 more
core +4 more sources
PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST
Рациональная фармакотерапия в кардиологии, 2015 Apixaban is a "new" oral anticoagulant, direct Xa factor inhibitor with a good evidence base of the efficacy in the prevention of ischemic stroke in patients with atrial fibrillation.
D. A. Sychev +6 more
doaj +3 more sources